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Abstract
Background: There is no generally accepted medical or surgical treatment to stop the progressive
course of retinitis pigmentosa. Previous studies have suggested lutein as a potential treatment with
positive effects on macular pigment density. The objective of this study was to examine the effect
of lutein supplementation on preservation of visual function in patients with retinitis pigmentosa
(RP)
Methods: In a double-masked randomized placebo-controlled phase I/II clinical trial with a cross-
over design, 34 adult patients with RP were randomized to two groups. One group, consisted of
16 participants, received lutein supplementation (10 mg/d for 12 wks followed by 30 mg/d) for the
first 24 weeks and then placebo for the following 24 weeks, while the other group included 18
participants for whom placebo (24 weeks) was administered prior to lutein. Visual acuity, contrast
sensitivity, and central visual field were measured at different illumination levels at baseline and
every week using a PC-based test at home.
Results: For visual acuity (VA) at normal illumination level, treatment with lutein reduced logMAR,
i.e. improved VA, but this effect was not statistically significant. The changes in normal (100%), low
(4%), and very low (0.1%) illumination log CS were not statistically significant (p-values: 0.34, 0.23,
and 0.32, respectively). Lutein had a statistically significant effect on visual field (p-value: 0.038) and
this effect increased in the model assuming a 6-week delay in effect of lutein. Comparing the
development of vision measures against the natural loss expected to occur over the course of 48
weeks, most measures showed reduced decline, and these reductions were significant for normal
illumination VA and CS.
Conclusion: These results suggest that lutein supplementation improves visual field and also might
improve visual acuity slightly, although these results should be interpreted cautiously. As a
combined phase I and II clinical trial, this study demonstrated the efficacy and safety of lutein
supplementation.
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Background
Retinitis pigmentosa (RP) is the name used to designate a
heterogeneous group of inherited progressive retinal dys-
trophies, characterized by photoreceptor degeneration,
which initially affects the rod photoreceptors and the
peripheral retina and often leads to legal and eventually
functional blindness. It is estimated that about 1/5000 to
1/4000 individuals have RP worldwide[1,2]. Since no
generally accepted medical or surgical treatment can stop
the course of the disease, several researchers have under-
taken informal or formal studies with vitamins and other
nutritional supplements in hopes of improving patients'
functional vision, or at least slowing down the course of
the disease. A randomized controlled clinical trial demon-
strated that vitamin A supplementation (15,000 IU/day)
reduces the loss of the remaining electroretinogram; [3]
despite some critical reviews, [4-6] it raised the hope for
effective supplement-based treatments that can slow dis-
ease progression. Others have reported a beneficial effect
of docosahexaenoic acid (DHA) in retinitis pigmentosa
[7,8].
Lutein, as a carotenoid assumed to play a preventive role
in macular diseases, [9] has been cited as a potential ther-
apeutic modality that can help in preserving the visual
function of patients with RP. Dietary modification and
supplementation with lutein increase the macular pig-
ment density [10,11] and several studies have shown the
protective effect of long-term high dietary intake of caro-
tenoids like lutein and zeaxanthin in reducing the risk of
age-related macular degeneration. [12-14] A few uncon-
trolled studies have shown the effect of lutein supplemen-
tation in increasing the macular pigment density and
improvement in visual acuity and central visual field
(CVF) diameter in normally-sighted individuals and in RP
and AMD patients [15-17]. These findings are suggestive
of a possible benefit of lutein in RP patients. To our
knowledge, the present study is the first randomized pla-
cebo-controlled double-masked clinical trial of lutein
supplementation in Retinitis Pigmentosa; we could find
no reference to similar studies in a computerized search of
the major medical literature databases.
Design
The study was a double-masked randomized placebo-con-
trolled clinical trial with a crossover design. As it investi-
gated both safety and efficacy of the supplements, and
compared the effects of two supplementation levels to
those of placebo, it can be classified as a combined phase
I/II clinical trial.
Methods
Setting
The study was carried out with approval from the Johns
Hopkins University, School of Medicine Institutional
Review Board (IRB) and Informed Consent was obtained
from the participants in accord with Helsinki Declaration
and following careful explanation of all study conditions
and procedures. The study was conducted at the Lions
Vision Center, Wilmer Eye Institute, Johns Hopkins Uni-
versity between May 2001 and November 2002.
Study population
Participants were adult patients with diagnosed retinitis
pigmentosa whose binocular central visual field was con-
stricted to less than 30° from fixation in all directions.
Patients were excluded from the study if at baseline: (1)
their central vision was deteriorated beyond 20/100 visual
acuity; or (2) they had abnormal liver function tests,
defined by increase in liver aminotransferases, alkaline
phosphatase, and serum bilirubin levels beyond the
upper normal limit. Results for 34 participants complet-
ing the study, including 21 women and 13 men with a
mean age 49.2 ± 9.0 years, are presented here. Figure 1
demonstrates the flow diagram of recruitment and group
assignment process.
Intervention
The study population was divided into two groups and
was followed for 48 weeks. Under a crossover design one
group (washout group, group I), consisting of 16 partici-
pants, received lutein capsules during the first half of the
study period (24 weeks) and indistinguishable placebo
capsules during the second half, while the other group
(buildup group, group II) included 18 participants who
received placebo during the first half and lutein in the sec-
ond half. Lutein supplementation in both groups started
with 10 mg/day for 12 weeks followed by 30 mg/day for
the following 12 weeks (Figure 2).
There have been suggestions in the literature that long-
term supplementation of a single carotenoid may inhibit
absorption of other carotenoids from the diet [18]. There-
fore, all participants were offered multivitamin supple-
mentation (Centrum Performance; 1 tablet/day), starting
4 weeks prior to the lutein/placebo supplementation.
Randomization
Each participant received a unique subject code, consist-
ing of a digit and a letter, e.g. 7a or 4b. The digit was drawn
randomly by study group (odd for group I, even for group
II); the letter represented the order of enrollment into the
study group. All participants and study personnel were
masked to the association of the odd/even assignment
and supplementation order; this masking remained in
effect until the end of the study. Randomization was strat-
ified along five dimensions thought to have a possible
correlation with lutein uptake and/or visual function in
RP, i.e., gender, skin color (light vs. dark), iris color (blue,
green/hazel, or brown), clinical evidence of cystoid macu-BMC Ophthalmology 2006, 6:23 http://www.biomedcentral.com/1471-2415/6/23
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Flow diagram of study participants Figure 1
Flow diagram of study participants.
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Assessed for eligibility (n = 62 
Randomized (n=45)
Lost to follow -up: 
Did not report the test results (n=1) 
Discontinued intervention (n=4)
Excluded (n= 7)
Not meeting inclusion criteria (n= 1)
Unable to participate (n=5)
Refused to participate (n=1)
Atypical cases of RP 
Allocated to lutein then placebo (n=20 )
Received allocated intervention 
(n=20)
Did not receive allocated intervention   
(n= 0)   
Allocated to placebo then lutein (n= 25)
Received allocated intervention 
(n=23)
Did not receive allocated intervention   
(n=2)  Reason: unable to participate
Lost to follow -up: 
Discontinued intervention (n=2) 
Analyzed (n= 16 )
Excluded from analysis   (n=0 )
Build-up Group 
(Group II)
Washout Group 
Assessed for eligibility (n = 62) 
Lost to follow -up: 
Excluded (n= 7)
Not meeting inclusion criteria (n= 1)
Unable to participate (n=5)
Refused to participate (n=1)
Lost to follow -up: 
Did not report the test results (n= 2)
Analyzed (n= 18 )
Excluded from analysis  (n=0)                                   
Build-up Group  Washout Group 
(Group I)
N=18
N=20 N=23
N=16BMC Ophthalmology 2006, 6:23 http://www.biomedcentral.com/1471-2415/6/23
Page 4 of 12
(page number not for citation purposes)
lar edema (CME), and use of vitamin A supplements, so
that near-equal numbers of participants with these charac-
teristics were allocated to each group. A retina specialist
examined prospective participants for cystoid macular
edema, while the color of iris and skin were judged by the
study coordinator. All supplement bottles were marked
for subject ID and dispensing order, but otherwise indis-
tinguishable; they were dispensed by the principal inves-
tigator.
Outcome measures
Our specific objectives were to evaluate the effect of lutein
on visual acuity, contrast sensitivity and central visual
field, in comparison with placebo. The primary outcome
measure for the study was ETDRS visual acuity recorded in
the laboratory, supplemented with a number of secondary
lab-based visual function measures. Outcomes recorded
in the lab has been reported elsewhere [19]. Here we
report on an alternate set of secondary vision measures
collected weekly through personal computers. All meas-
ures were recorded in one eye only; this was usually the
better eye, but in some participants, whose better eye had
VA better than 20/20 in the lab (logMAR <0), the worse
eye was selected as the study eye. Visual acuity (VA), con-
trast sensitivity (CS) and central visual field radius (CVF)
were recorded at normal screen intensity, and using 4%
(low; using NoIR U23 wrap-around shields) and 0.1%
(very low; using welders' goggles with Schott #6 glass and
Kodak Wratten ND1 filters) illumination. Visual acuity
and contrast sensitivity were recorded as the logarithm of
the minimum angle of resolution (logMAR) and the loga-
rithm of contrast sensitivity (log CS), respectively. The vis-
ual field radius was measured along meridians at 15
degree (normal illumination; from 0 to 345 degrees) and
30-degree (low and very low illumination) intervals, and
the mean radius was converted to the logarithm of the ret-
inal area (in mm2) [20].
Participants installed and ran the test software under Win-
dows; a secure file transfer protocol was used to upload
the results to a server at our center. Validity and reliability
of these tests was established independently [21]. The
overall correlation between PC- and lab- measured VA
and CS in normal illumination was 0.92 and 0.95, respec-
tively (unpublished data). All participants performed the
visual function tests weekly on their home or work PCs,
keeping day and hour as constant as possible. Five partic-
ipants who did not have access to a computer performed
the same weekly tests on a PC in our lab. During the initial
clinic visit, all subjects received careful instruction regard-
ing the test, including a detailed manual. Also, on-screen
reminders were designed before each test to help the sub-
jects with correct setup conditions. To standardize test
conditions as much as possible, all subjects were given
150 and 25 cm distance gages, to be attached to the PC
monitor (25 cm for visual field, 150 cm for acuity and
contrast sensitivity tests), a black eye patch to cover the
non-tested eye, NoIR U23 filters and welders goggles to
adjust the level of illumination, and a disposable camera,
so the proper test setup and execution could be verified.
During each trial a test letter was shown in the center of
the screen for 3 seconds or until the subject right-clicked
the mouse to shorten the trial, and the subject then had to
pick a match among 10 letters (C,D,H,K,N,O,R,S,V,Z).
The visual field tests were based on the assumption that
all patients had a central island, and the test algorithm
flashed a dot along one of 24 axes (15° increments; 12
axes, i.e., 30° increments, at the two lower intensities),
straddling the putative scotoma border; these tests are
akin to Goldmann visual fields with a static (flashing)
rather than kinetic (moving) test dot. All tests used a Baye-
sian adaptive algorithm [22] to find the threshold in a
minimum number of trials: 24 for full intensity VA, 16 for
all other VA and CS tests and for each CVF axis.
Allocation of lutein supplementation and placebo in two groups during The Trial Note: All participants received multi-vitamin  supplement beginning 4 weeks before and continuing throughout the study Figure 2
Allocation of lutein supplementation and placebo in two groups during The Trial Note: All participants received multi-vitamin 
supplement beginning 4 weeks before and continuing throughout the study.
Group I 
(Washout Group) 
(N=16) 
Lutein 
(10 mg/day) 
Lutein 
(30 mg/day)  Placebo 
Group II 
(Buildup Group) 
(N=18) 
Placebo  Lutein 
(10 mg/day) 
Lutein 
(30 mg/day) 
Time (weeks)            Start                   12                      24                     36                       48 wk BMC Ophthalmology 2006, 6:23 http://www.biomedcentral.com/1471-2415/6/23
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Sample size and statistical analysis
The sample size calculation for this study was based on
results from a pilot study of lutein supplementation, in
which high contrast VA was the primary outcome[16]. The
pilot study showed a mean effect of 7.0 letters and a mean
standard deviation (SD) across subjects of 6.7 letters. With
α = 0.05 and β = 0.20, and assuming a similar SD across
subjects, we determined that a group size of 14 would be
needed to detect an effect of 7.0 letters, or a group size of
26 to detect 5.25 letters (this reduced difference assumes
a 25% placebo effect) [23]. These calculations did not take
into account the increased power derived from multiple
measurements. Since this was a phase I/II clinical trial, a
sample size of 30–50 was considered prudent for this
study. Analysis was performed based on intention-to-treat
and using a multiple linear regression model with Gener-
alized Estimating Equations (GEE) [24]. We also repeated
the analysis using random effects and population-aver-
aged linear mixed models. The two latter models are
slightly different from GEE in the method of handling cor-
relation in the data and, as expected, the analysis using
these models did not demonstrate any significant differ-
ences, indicating the robustness of our models to the
method of handling correlation. In these models, log-
MAR, log CS, and log retinal area were used as outcome
variables and treatment (lutein vs. placebo), period (first
vs. second 24-weeks of the study), time (as number of
weeks within each period), age, the baseline value of each
measure, vitamin A use (yes vs. no), iris color (in three cat-
egories; light/dark blue, green/hazel, and light/dark
brown) and the interaction terms of treatment*time,
period*treatment, and period*time were used as predic-
tor covariates. Since we were interested in treatment
effects and visual function test changes across the follow-
up period, we forced time and treatment to the model
even if they were found not to provide significant contri-
butions. Other covariates were removed from the model
in a backward stepwise elimination if they were found not
to be significant. The most parsimonious models includ-
ing significant and forced covariates are reported here.
Baseline characteristics were checked for any imbalances.
There was no significant difference in baseline characteris-
tics of the subjects who withdrew did not complete the
study and study participants. Since it was hypothesized
that lutein effects might be delayed by about one visit to
our center (6 weeks), a sensitivity analysis was done for
each visual function measure to test this hypothesis.
Results
Baseline data
Data are reported here for the 34 participants who submit-
ted a sufficient number of PC-based test data sets to allow
reliable analysis of both study phases (at least 8 measures
per study phase). Mean and standard deviation for the
duration of PC-based data collection were 46.7 ± 13.7
weeks in the washout group, and 45.3 ± 8.9 weeks in the
buildup group. Table 1 summarizes the baseline data for
the two groups. None of the baseline data, except age (by
which the participants were not stratified) and log CS at
4% illumination showed a considerable imbalance
between two groups. Regarding the imbalance in age dis-
tribution, we included age in all GEE models and as
explained below, it did not have a significant effect in any
model, except in the model for contrast sensitivity at low
(4%) illumination level.
Lutein effects
The most significant predictors of visual function at all
three levels of illumination were the baseline values (p
value <0.001 in all models).
Visual acuity
Table 2 summarizes the final GEE models for logMAR
(visual acuity) at three levels of illumination, i.e. normal,
low (4%), and very low (0.1%). According to the final
model for visual acuity (log MAR) at normal illumination
(table 2), treatment with lutein slightly reduced logMAR,
i.e. slightly improved the VA, of the participants, but not
to a statistically significant degree.
At the low (4%) illumination level, participants ingesting
vitamin A supplements tended to have better VA (p value:
0.04), independently of other covariates. The interaction
between period and time was significant (p value: 0.04);
therefore, it is not possible to interpret the effects of
period and time directly from the model. Stratified analy-
sis, using two models for the two periods, showed a slight
non-significant reduction in logMAR of the participants
who received lutein in first half of the study (p value:
0.57), while those who received lutein in second half of
the study had a slight non-significant increase in logMAR
(p value: 0.42). These results should be interpreted cau-
tiously, since by stratification of data on period we lose
some power of our crossover design.
In the model for VA at very low illumination level (0.1%),
the interaction between period and treatment was signifi-
cant (p value: 0.011), suggesting that the effect of treat-
ment depends on period. If we insert the coefficients for
period, treatment, and period*treatment into the model,
then in the washout group this outcome measure was
slightly better (lower) in the first than in the second half
(-0.076 and -0.065, respectively). In the buildup group,
the difference between average logMAR in the first and the
second half of the study was very small (0.004).
Contrast sensitivity
Table 3 summarizes the final GEE models for log CS (con-
trast sensitivity) at three levels of illumination, i.e. nor-
mal, low (4%), and very low (0.1%). The model for log CSBMC Ophthalmology 2006, 6:23 http://www.biomedcentral.com/1471-2415/6/23
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at normal illumination shows a non-significant increase
in log CS, i.e. improvement in contrast sensitivity, across
time (p value: 0.31) after adjustment for period and type
of treatment. Also participants on treatment with lutein
showed a non-significant trend towards higher CS (p
value: 0.34). But period did have a significant effect on log
CS at normal illumination, suggesting that, controlled for
t y p e  o f  t r e a t m e n t ,  l o g  C S  i s  h i g h e r  d u r i n g  t h e  s e c o n d
phase of the study than during the first phase (p value:
0.035). Stratified analysis of normal illumination log CS
values showed a non-significant increase during both
periods.
The low (4%) illumination log CS values were higher
when participants were receiving lutein supplementation,
which means an improvement in CS, but this change was
not statistically significant (p value: 0.24). The model for
CS at low (4%) illumination is the only model in which
age had a significant effect, i.e. lower CS in older partici-
pants. Since there was a significant interaction between
period and time in this model, the effect of these two var-
iables could not be estimated directly from the coeffi-
cients, but this interaction suggests that low illumination
log CS was declining in the second half of the study only.
The model for CS at very low (0.1%) illumination was
developed using the data from 32 cases, since two of the
participants in the buildup group could not see the stim-
ulus at this illumination level. No significant effects were
found, other than the baseline value.
Central visual field
In a similar model for log retinal area, participants did not
have a significant change. The mean log retinal area when
the participants were on lutein was 0.018 higher (95% CI:
0.001, 0.036, p value: 0.038) than when they received pla-
cebo, but the visual field deteriorated throughout the
Table 1: Baseline Values and Frequencies by Treatment Group
Group I Group II
Variable* (Wash-out Group) (N = 16) (Build-up Group) (N = 18)
Gender (Female to Male) 11/5 10/8
Age 52.4 ± 1.7 46.4 ± 2.3
Vitamin A Consumption 6 5
Iris color
Dark Brown/Light Brown 6 5
Green/Hazel 6 6
Dark Blue/Light Blue 4 7
Skin Color†
Pale 2 3
Pale 10 14
Light Brown 0 0
Dark Brown 3 2
Cystoid Macular Edema 5 7
Visual Acuity (Log MAR)
Normal Illumination 0.275 ± 0.062 0.280 ± 0.050
4% Illumination 0.497 ± 0.065 0.591 ± 0.072
0.1% Illumination 0.902 ± 0.062 0.891 ± 0.065
Contrast Sensitivity (Log CS)
Normal Illumination 1.471 ± 0.105 1.346 ± 0.114
4% Illumination 1.184 ± 0.090 0.928 ± 0.118
0.1% Illumination 0.708 ± 0.102 0.658 ± 0.091
Log Retinal Area (square mm) 0.778 ± 0.336 0.970 ± 0.340
* Continuous variables are presented as mean ± standard error, while categorical and binomial variables are presented as absolute frequency.
† Skin color was defined based on the phenotype of the participant. Pale+ refers to the very light skin color that burns rapidly in exposure to the 
sun.BMC Ophthalmology 2006, 6:23 http://www.biomedcentral.com/1471-2415/6/23
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study (change per week: -0.2%, 95% CI: -0.003, -0.001, p
value< 0.001). This reduction is consistent with about
11.4% decrease in log retinal area per year. Also partici-
pants who were taking vitamin A had a significantly larger
visual field (difference in average log retinal area: 0.094;
95% CI: 0.008, 0.179, p-value: 0.032), but this difference
did not change over the course of the study.
The overall changes in mean logMAR, mean log CS, and
VF over time are illustrated in Figures 3 and 4. Mean val-
ues were averaged over six-week intervals; this might mask
any within-interval changes, but this is not likely: The
shallow slopes of the graphs are consistent with the small
coefficients in our GEE models.
Further analyses
Several sensitivity analyses were performed to verify the
results and test the assumptions used in the analysis.
Using a random effects model instead of population-aver-
age model and imputing missing values did not change
the results of the study.
As another ancillary analysis we checked for a possible
delayed effect of lutein supplementation, under the
hypothesis that the effect of lutein may only appear after
six or twelve weeks. Using a model with 6 weeks delay, the
effect of lutein on VA at normal and low (4%) illumina-
tion levels did not show any qualitative changes com-
pared to the model without delayed effect assumption.
For the remaining measures some changes were found,
however: The significant period effect observed for VA at
very low (0.1%) illumination level was removed, while
the treatment effect lost significance. Similarly, the period
effect seen in the model for CS at normal illumination dis-
appeared in the delayed effect model. Furthermore, the
interaction between period and time for CS at low (4%)
illumination lost significance. In this model, the average
log CS at normal illumination was slightly (0.017 unit,
95% CI -0.014, 0.049, p value: 0.30) higher when partici-
pants were on lutein than when they were receiving pla-
cebo.
In the model assuming a 6-week delay effect of lutein on
VF, lutein had a highly significant effect in preserving VF
and the mean log retinal area when participants were on
lutein was 0.029 (95% CI: 0.012, 0.047, p-value:0.001)
higher than when they were on placebo. As expected, this
change in analysis did not affect the rate of CVF loss, nor
the observed constant difference between vitamin A users
and non-vitamin A users. Table 4 summarizes the regres-
sion models for log retinal area without and with the 6-
week delay assumption.
The other additional analysis performed was a compari-
son between changes in visual function under treatment
and the natural course of retinitis pigmentosa, consider-
ing that this natural course entails a gradual deterioration
of visual function. The rate of this deterioration is esti-
Table 2: Changes in Visual Acuity (LogMAR) at Different Levels of Illumination*
Level of Illumination Normal (100%) Low (4%) Very Low (0.1%)
Covariates§ Coefficient¶ (95% CI) P value Coefficient (95% CI) P value Coefficient (95% CI) P value
Treatment† -0.0002 (-0.0131,0.0128) 0.981 0.0054 (-0.0137,0.0246) 0.578 -0.0762 (-0.139, -0.0131) 0.018
Period -‡ - -0.0448 (-0.083,-0.0066) 0.022 -0.0654 (-0.134, -0.0132) 0.061
Time† (number of weeks) -0.0010 (-0.0026, 0.0007) 0.250 -0.0026 (-0.0048,-0.0003) 0.025 -0.0014 (-0.0027,-0.0001) 0.037
A g e ------
Vitamin A Use - - -0.0701 (-0.1357,-0.0046) 0.036 - -
I r i s  c o l o r ------
Period × Treatment - - - - 0.1452 (0.0339, 0.2565) 0.011
T r e a t m e n t  ×  T i m e ------
Period × Time - - 0.0023 (0.0001, 0.0046) 0.044 - -
Baseline LogMAR 0.9783 (0.8933, 1.0634) <0.001 1.0086 (0.8909, 1.1268) <0.001 0.9290 (0.8416,1.0164) <0.001
Intercept 0.108 (-0.187, 0.402) 0.474 0.0265 (-0.0386, 0.0916) 0.424 0.0949 (0.0088, 0.181) 0.031
* Based on the GEE linear regression model
† Covariates forced to the model.
‡ Covariate removed due to non-significant contribution to the model (p value > 0.05).
§Description of covariates:
• Period: 0 in the first 24 weeks of the study, 1 in the second 24 weeks
• Treatment: 0 for placebo, 1 for lutein supplementation
• Time: Elapsed time within each 24-week period of the study (in weeks)
• Age: Age of the patients at baseline (in years)
• Vitamin A Use: 0 for participants not using, 1 for those using vitamin A supplements
• Iris color: Categorical variable: 1. Light/Dark Blue 2. Green/Hazel 3. Light/Dark Brown
¶The coefficient indicates the change in LogMAR units per unit change in the covariate.BMC Ophthalmology 2006, 6:23 http://www.biomedcentral.com/1471-2415/6/23
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mated to be about 15–17% in year loss for VF [24,25] and
about 3–5% annual loss for VA and CS (unpublished data
from the same patient sample [24] as the visual field
data). Assuming a 5% annual rate of increase in logMAR
as the natural course of disease, treatment with lutein
resulted in significant improvement in VA at normal illu-
mination (p value: 0.022), in low illumination VA (p
value: 0.001) and also in VA at very low illumination level
(p value <0.001). Also assuming a 5% annual rate of
decrease in log CS, the CS at normal illumination level
increased significantly (p value: 0.030), but the low (4%)
and very low (0.1%) level log CS values did not show sig-
nificant changes in these models. In the model assuming
a probable 15–17% annual reduction in log retinal area,
the changes in log retinal area during the study did not
have a statistically significant difference with the expected
reduction.
Adverse effects
No significant adverse effects were seen in participants
while they were taking lutein supplementation. One par-
ticipant on lutein, and two participants on placebo (and
multivitamin) had impaired liver function tests at one of
their 6-week visits, but in all three the serum liver enzymes
levels returned to the normal range when tests were
repeated. Two participants had significant intolerance to
multivitamin ("stomach upset") at the start f the study,
prior to ingestion of lutein or placebo, and ceased multiv-
itamin ingestion early in the study.
Summary of results
No significant adverse effects were seen in participants
while they were taking lutein supplementation. For VA at
normal illumination level, treatment with lutein reduced
logMAR, i.e. improved VA, but this effect was not statisti-
cally significant. The changes in normal (100%), low
(4%), and very low (0.1%) illumination log CS were not
statistically significant (p-values: 0.34, 0.23, and 0.32,
respectively). Lutein had a statistically significant effect on
VF (p-value: 0.038) and this effect increased in the model
assuming a 6-week delay in effect of lutein.
Discussion
Previous studies have suggested a beneficial effect of
lutein on macular pigment [8-10,26]. As mentioned
above, we are unaware of any previous randomized pla-
cebo-controlled clinical trial of lutein in RP patients.
Therefore, one issue was the safety of lutein supplementa-
tion in these RP patients. Our study confirmed that lutein
supplementation at 10–30 mg/day for up to 6 months is
safe, with fewer adverse effects than multivitamin.
In order to have a better understanding of the effects of
lutein and the pattern of these effects across time, visual
function tests were collected weekly, using PC-based tests.
Having this amount of data, we performed various types
of analysis to test different hypotheses, although the sam-
ple size of the study to some extent restricted the strength
of these further analyses. While we tested numerous mod-
els, we resolved to report the most conservative and robust
estimates to make sure that we would not make unwar-
ranted claims. Our results were consistent with what we
found from analysis of visual function tests performed in
the lab [19].
There is weak evidence in favor of a positive effect of
lutein supplementation in preserving VA in patients with
RP. As explained above, it slightly improved VA at normal
illumination level, although this was not statistically sig-
nificant. The non-significant results may be due to lack of
enough power to detect such an effect and/or confound-
ing by delayed effect of lutein. Considering a 6-week delay
Table 3: Changes in Contrast Sensitivity (Log CS) at Different Levels of Illumination Ω
Level of Illumination Normal (100%) Low (4%) Very Low (0.1%)
Covariates§ Coefficient¶ (95% CI) P value Coefficient (95% CI) P value Coefficient (95% CI) P value
Treatment† 0.0154 (-0.0164,0.0471) 0.342 0.0408 (-0.0273,0.1089) 0.241 -0.0184 (-0.0545, 0.0176) 0.316
Period 0.0351 (0.0025,0.0677) 0.035 0.0014 (-0.0853,0.0880) 0.975 -‡ -
Time† (number of weeks) 0.0008 (-0.0008, 0.0025) 0.313 0.0001 (-0.0034, 0.0037) 0.934 -0.0009 (-0.0024,0.0006) 0.237
Age -‡ - -0.0049 (-0.0061,-0.0038) <0.001 - -
V i t a m i n  A  U s e ------
Iris color - - - - - -
Period × Treatment - - - - - -
Treatment × Time - - - - - -
Period × Time - - -0.0028 (-0.0055,-0.0001) 0.042 - -
Baseline Log CS 0.9865 (0.9289, 1.0440) <0.001 0.9451 (0.8496, 1.0406) <0.001 0.9721 (0.9003,1.0440) <0.001
Intercept 0.0133 (-0.0705, 0.0971) 0.755 0.2781 (0.1374,0.4188) <0.001 0.459 (-0.0119, 0.1037) 0.119
Ω Variables and model criteria: See Table 2.
¶ The coefficient indicates the change in Log CS units per unit change in the covariate.BMC Ophthalmology 2006, 6:23 http://www.biomedcentral.com/1471-2415/6/23
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Changes of mean LogMAR and mean log CS at different illumination levels in Washout and Buildup groups Figure 3
Changes of mean LogMAR and mean log CS at different illumination levels in Washout and Buildup groups. Note: Bars indicate 
1.96*standard error
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in effect of lutein, the effect size increased and even in low
illumination level the non-significant negative effect of
lutein changed to a positive effect. It should be underlined
that there are modest improvements in VA in comparison
with the natural course of the disease, which is a gradual
deterioration of VA.
The evidence for the positive effect of lutein on CS was
weaker, although lutein supplementation resulted in non-
significant improvement of contrast sensitivity at normal
and low illumination levels. Again, when compared to an
expected decline due the natural course of the disease, a
marginally significant benefit of lutein would be found.
The log visual field area, finally, did show a beneficial
effect of lutein supplementation, although the gradual
loss of visual field was not significantly slowed.
One important caveat in evaluating the effects of lutein
supplementation is related to the pharmacokinetics and
pharmacodynamics of the supplement. Our hypothesis is
that the effect of lutein starts several weeks after the start
of supplementation and persists until at least several
weeks after stopping the treatment. In our study we tested
a six-week delay in the effect of lutein and we found sev-
eral indications in support of this hypothesis. Assuming
that the effects of lutein appear after 6 weeks increased the
coefficients of lutein effect in VA models, i.e. increased the
difference between mean logMAR of the participants
when they were receiving lutein vs. when they were on
placebo. Particularly, at very low illumination, the signif-
icant period effect in the original model was removed in
the delayed effect model. This suggests that the period
effect can be due to this delayed effect of lutein. Further-
more, stratified analysis showed that in the first half of the
study lutein had a non-significant positive effect, while in
the second half the relative effect of lutein was signifi-
cantly negative, i.e., those no longer on 30 mg/day lutein
fared better than those just starting the 10 mg/day regi-
men. This finding supports our hypothesis that the effect
of lutein appears with some delay and may last for weeks
after treatment. In other words, the significantly better VA
in participants receiving placebo in the second half of the
study relative to their counterparts on 10 mg/day can be
the effect of high-dose lutein supplementation received in
the last weeks of the first half, rather than a negative effect
of low-dose lutein received by the other subject group in
the second half. On the other hand, for participants who
were receiving lutein in second half of the study (buildup
group), there may not have been enough time for the
effect of lutein to reach its optimal effective dosage, since
its delayed effect appears near the end of study. Analysis
of VF data under a 6-week delay assumption increased
both the magnitude and the statistical significance of the
effect of lutein on log retinal area. Also, our comparison
of the changes in the participants' visual function with the
gradual deterioration of visual function that would be
expected based on previous studies, [27,28] suggests a
Table 4: Visual field regression model. Ω
Model Without 6-Week Delay Assumption With 6-Week Delay Assumption
Covariates§ Coefficient¶ (95% CI) P value Coefficient (95% CI) P value
Treatment† 0.0183 (0.0010,0.0355) 0.038 0.0292 (0.0118,0.0466) 0.001
Period -‡ ---
Time† (number of weeks) -0.0022 (-0.0034,-0.0010) <0.001 -0.0023 (-0.0034,-0.0011) <0.001
A g e ----
Vitamin A Use 0.0937 (0.0081, 0.1793) 0.032 0.0941 (0.0080, 0.1803) 0.032
I r i s  c o l o r ----
P e r i o d  ×  T r e a t m e n t ----
T r e a t m e n t  ×  T i m e ----
P e r i o d  ×  T i m e ----
Baseline Log Retinal Area 0.8965 (0.8309, 0.9621) <0.001 0.8957 (0.8297, 0.9617) <0.001
Intercept 0.1325 (0.0583, 0.2067) <0.001 0.1299 (0.0554,0.2043) 0.001
Ω For description of variables and coefficients: See Table 2.
¶ The coefficient indicates the change in log (visual field area) per unit change in the covariate.
Changes of the visual field (mean log retinal area) at normal  illumination level in Washout and Buildup groups Figure 4
Changes of the visual field (mean log retinal area) at normal 
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benefit of lutein supplementation in preserving visual
function.
Our results support a positive difference in the VF of RP
patients taking Vitamin A, but no similar difference in VA
and CS. However, in view of the relatively small number
of participants using vitamin A supplementation such a
difference may have been accidental.
Another caveat in our study pertains to the use of multiv-
itamin in both groups. Some findings that could not be
credited to lutein in the treatment period of our study
might be attributable to one or more than one ingredients
of multivitamin. In fact, in our analysis, the visual func-
tion measures in our participants while on placebo were
better than the expected natural course of RP. Thus, while
part of this effect might be due to the delayed effect of
lutein; another explanation might be a beneficial effect of
multivitamin, the only treatment during that period. Due
to the small sample size of our study it is difficult to judge
the generalizability of these results, yet we believe that
they may apply to most patients with retinitis pigmentosa.
The eligibility criteria of our study population and the
method of sampling were designed to minimize the selec-
tivity of our participants and the demographic characteris-
tics of our study population confirmed this.
Limitation
Three important limitations of our study were the small
sample size, (justifiable for a phase I/II clinical trial), the
short follow-up duration, and the lack of a wash-out
period (based on the very long persistence of lutein in the
eye, in macular pigment and adipose tissue) [11,16,29].
As mentioned above, the study may not have had enough
power to detect minor differences between the groups;
also, it was difficult to check the effect of intervention with
delays of more than 6 weeks, as this would further have
limited the duration of available data due to the relatively
short study duration. The results seem to justify further
studies of possible benefits of lutein and multivitamin use
for RP patients.
Conclusion
Lutein appears to affect visual function in ways that may
differ for different measures. It has a positive effect in pre-
serving the VF of the participants and this effect probably
emerges after a number of weeks. For VA, there is modest
evidence of delayed effectiveness of lutein. Finally, we did
not find any significant effect of lutein in preserving CS
even under the assumption of a delayed effect. Further
studies with larger sample sizes and longer follow-up
times will be necessary to test these hypotheses. In addi-
tion, possible effects of multivitamin on RP deserve fur-
ther study. Our results suggest that a good nutritional
supplement in RP may be a combination of lutein, vita-
min A and multivitamin.
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